ASCO 2023 Highlights on the MIRASOL trial in PT-resistant adv. high-grade epithelial Ovarian Cancer
Reporting from ASCO 2023, Rowan Miller discusses practice changing results from the MIRASOL study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian cancer with high folate receptor-alpha expression.
Abstract: LBA5507 - Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression, presented by Kathleen Moore.
The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here https://oncologypro.esmo.org/oncology...
Produced by the European Society for Medical Oncology
http://www.esmo.org
Смотрите видео ASCO 2023 Highlights on the MIRASOL trial in PT-resistant adv. high-grade epithelial Ovarian Cancer онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь European Society for Medical Oncology (ESMO) 08 Июнь 2023, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 1,892 раз и оно понравилось 24 людям.